Genomes, transcriptomes, and proteomes: Molecular medicine and its impact on medical practice

Archives of Internal Medicine

Volumn 163, Issue 2, 2003, Pages 190-198

  Gerling, Ivan C ^a,b,c   Solomon, Solomon S ^a,b,c   Bryer Ash, Michael ^a,b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE; PROTEOME; TRANSCRIPTION FACTOR; TRANSCRIPTOME;

ALLELE; CLINICAL PRACTICE; DIABETES MELLITUS; DNA SEQUENCE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC DISORDER; GENETICS; GENOME; HEALTH CARE COST; INSULIN DEPENDENT DIABETES MELLITUS; MOLECULAR BIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION;

DIABETES MELLITUS; GENE EXPRESSION PROFILING; GENETIC SCREENING; HUMAN GENOME PROJECT; HUMANS; MOLECULAR BIOLOGY; PROTEOME;

EID: 0037467722     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.2.190     Document Type: Review

References (60)

1. DiMichele D, Neufeld EJ. Hemophilia: a new approach to an old disease. Hematol Oncol Clin North Am. 1998;12:1315-1344.
2. Hift RJ, Meissner PN, Corrigall AV, et al. Variegate porphyria in South Africa, 1688-1996: new developments in an old disease. S Afr Med J. 1997; 87:722-731.
3. Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature. 2000;405:827-836.
4. Quinn N, Schrag A. Huntington's disease and other choreas. J Neurol. 1998;245:709-716.
5. Emmett A. The human genome. Scientist. 2000; 14:1-19.
6. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921.
7. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001; 291:1304-1351.
8. National Research Council Committee on Mapping and Sequencing the Human Genome. Mapping and Sequencing the Human Genome. Washington, DC: National Academy Press; 1988.
9. Kadar A, Glasz T. Development of atherosclerosis and plaque biology. Cardiovasc Surg. 2001; 9:109-121.
10. Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the haemoglobinopathies. Baillieres Clin Haematol. 1998;11:1-51.
11. Laham RJ, Simons M, Sellke F. Gene transfer for angiogenesis in coronary artery disease. Annu Rev Med. 2001;52:485-502.
12. Parkman R, Weinberg K, Crooks G, Nolta J, Kapoor N, Kohn D. Gene therapy for adenosine deaminase deficiency. Annu Rev Med. 2000;51:33-47.
13. Smith AE. Gene therapy: where are we? Lancet. 1999;354(suppl 1):SI1-SI4.
14. Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem: the dual inhibition concept. Pharmacol Res. 2001; 43:429-436.
15. Collins FS. Shattuck lecture: medical and societal consequences of the human genome project. N Engl J Med. 1999;341:28-37.
16. Ommen GJB, Bakker E, Dunnen JT. The human genome project and the future of diagnostics, treatment, and prevention. Lancet. 1999;354(suppl 1): SI5-SI10.
17. Bonn D. International consortium SN(i)Ps away at individuality. Lancet. 1999;353:1684.
18. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928-933.
19. Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405:857-865.
20. Risch NJ. Searching for genetic determinants in the new millennium. Nature. 2000;405:847-856.
21. Srivastava D. Genetic assembly of the heart: implications for congenital heart disease. Annu Rev Physiol. 2001;63:451-469.
22. Todd JA. Interpretation of results from genetic studies of multifactorial diseases. Lancet. 1999; 354(suppl 1):SI15-SI16.
23. Hamadeh H, Afshari CA. Gene chips and functional genomics. Am Sci. 2000;88:508-515.
24. Pandey A, Mann M. Proteomics to study genes and genomes. Nature. 2000;405:837-846.
25. Gevaert K, Vandekerckhove J. Protein identification methods in proteomics. Electrophoresis. 2000; 21:1145-1154.
26. Davidsson P, Paulson L, Hesse C, Blennow K, Nilsson CL. Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. Proteomics. 2001;1:444-452.
27. Wilson RD. Amniocentesis and chorionic villus sampling. Curr Opin Obstet Gynecol. 2000;12:81-86.
28. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
29. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
30. Warner LE, Garcia CA, Lupski JR. Hereditary peripheral neuropathies: clinical forms, genetics, and molecular mechanisms. Annu Rev Med. 1999;50:263-275.
31. Owen MJ, Cardno AG. Psychiatric genetics: progress, problems, and potential. Lancet. 1999; 354(suppl 1):SI11-SI14.
32. Motulsky AG. If I had a gene test, what would I have and who would I tell? Lancet. 1999;354 (suppl 1):SI35-SI37.
33. Mehta A, Mason PJ, Vulliamy TJ. Glucose-6-phosphate dehydrogenase deficiency. Baillieres Best Pract Res Clin Haematol. 2000;13:21-38.
34. Hall AH, Kulig KW, Rumack BH. Drug- and chemical-induced methaemoglobinaemia: clinical features and management. Med Toxicol. 1986;1:253-260.
35. Wolf CR, Smith G, Smith RL. Pharmacogenetics. BMJ. 2000;320:987-990.
36. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986
37. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304-309.
38. Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: An attempt to prevent type 1 diabetes: DENIS Group. Diabetes. 1998;47:980-984.
39. Rakotoambinina B, Timsit J, Deschamps I, et al. Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients. Diabetes Care. 1995;18:1487-1490.
40. Lin-Su K, Kukreja A, Maclaren NK. Diabetes vaccines: a future to be realized. Diabetes Technol Ther. 2001;3:451-461.
41. Casares S, Brumeanu T D. Insights into the pathogenesis of type 1 diabetes: a hint for novel immunospecific therapies. Curr Mol Med. 2001;1:357-378.
42. Buyukgebiz A, Cemeroglu AP, Bober E, Mohn A, Chiarelli F. Factors influencing remission phase in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2001;14:1585-1596.
43. Adorini L, Gregori S, Harrison LC. Understanding autoimmune diabetes: insights from mouse models. Trends Mol Med. 2002;8:31-38.
44. Gottlieb PA, Eisenbarth GS. Insulin-specific tolerance in diabetes. Clin Immunol. 2002;102:2-11.
45. Chatenoud L. Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity: its relevance for treatment in established diabetes and islet transplantation. Diabetologia. 2001;44:521-536.
46. Dagogo-Jack S, Santiago JV. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med. 1997;157:1802-1817.
47. Medici F, Hawa M, Ianari A, Pyke DA, Leslie RD. Concordance rate for type II diabetes mellitus in monozygotic twins: actuarial analysis. Diabetologia. 1999;42:146-150.
48. Kyvik KO, Green A, Beck-Nielsen H. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. BMJ. 1995;311:913-917.
49. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Statistics. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 1995. NIH publication H96-3926.
50. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. 1997;5:177.
51. Geiss LS, Herman WH, Smith PH. Mortality in NIDDM. In: Harris MI, Cowie CC, Stern MP, et al, eds. Diabetes in America. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 1995:236.
52. Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract. 2000; 113(suppl):3-13.
53. Accili D, Kido Y, Nakae J, Lauro D, Park BC. Genetics of type 2 diabetes: insight from targeted mouse mutants. Curr Mol Med. 2001;1:9-23.
54. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994;43:1271-1278.
55. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312.
56. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11:327-332.
57. Sanchez JC, Chiappe D, Converset V, et al. The mouse SWISS-2D PAGE database: a tool for proteomics study of diabetes and obesity. Proteomics. 2001;1:136-163
58. Bonn D. Genetic testing and insurance: fears unfounded? Lancet. 2000;355:1526.
59. Petersen GM, Brensinger JD, Johnson KA, Giardiello FM. Genetic testing and counseling for hereditary forms of colorectal cancer. Cancer. 1999;86(11 suppl):2540-2550.
60. Lehmann LS, Weeks JC, Klar N, Biener L, Garber JE. Disclosure of familial genetic information: perceptions of the duty to inform. Am J Med. 2000; 109:705-711.